Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M., Schmidt, C. & DeFrancesco, L. Nature Biotechnology’s academic spinouts 2022. Nat Biotechnol 41, 1669–1678 (2023). https://doi.org/10.1038/s41587-023-02023-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-02023-z
